Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm pretty sure one of those PP funds is the short... and from the list, only Anson has the shares to cover.
http://thecse.com/sites/default/files/2017_03_30_Form_9_-_Amended_Notice_of_Completed_Private_Placement.pdf
They probably started shorting at a much higher point, and their profit is about 100k long shares, the 60 cent warrants, and whatever extra cash they milked above .42US.
So I just assume that the short amount is currently at zero (to be replaced by PP shares), making the net amount of the PP shares to be released around 3.3M shares, plus the warrants. 6 month mark is September 30th.
And I'm hoping for some great news in the next two weeks to put those shares in the money.
slowly but surely...
LXRP's Oral CBD Product to Be Tested by the University of British Columbia
- The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product
- TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x
- The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration
Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers.
Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.
Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…”
Details of the test results are expected to be released once the study is completed and the data are interpreted.
According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver.
An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017.
For more information, visit the company’s website at www.LexariaEnergy.com
nice little volume push into close, need to break back over .40 tomorrow
Which would suggest the short sits on avg above .42usd?
when their shares are released from the PP next month.
Latest short update is basically unchanged? When will this position cover?!
Almost all buying today that's good to see... $LXRP$
That I'd like to see!
Chris stated that we wouldn't recognize Lexaria at the end of this year. Maybe he knows something that he can't publicly share. Hmmm. I may have to apologize to Chris which I would gladly do.
Could be implemented as the standard. Timing is good to start releasing findings!
Maybe that's why Lexaria is working and testing with the Canadian government already, it would be an easy match.??
Measured dosage and consistent onset will be key to making edibles viable in the market place.
Enter LXRP.
Cool, thanks for the links.
Buy-Hold-Retire before your old,
Knife
Was forwarded some tweets about Canadian edibles legislation being discussed at #HESA, standing committee on health today.
Task Force Chair Anne McLellan doubles down, says edibles "absolutely have to be part of the regulated market going forward.” #HESA #cdnpoli
— Jeffrey Lizotte (@J_Lizotte) September 11, 2017
Takeaways from #HESA #C45 Session 1:
— Jeffrey Lizotte (@J_Lizotte) September 11, 2017
1. Health Canada admits for the first time that they're working on edible / value added product regs.
Edibles are on their way! We'll kind of...as soon as Health Canada can get regulations and policy drafted and passed. #HESA #CannabisAct
— Jarett Lalonde 🇨🇦 🇺🇦 🇮🇱 (@CalgaryJLO) September 11, 2017
Interested to see what new short numbers show tomorrow...
Way better website. Now looks like professional biotech versus the kinda fake looking healthy living style.
The LOI's are waiting for the test results to sign I would bet. Once they prove it, (which I'm confident they will) this will continue its ascent to $1 plus as the deals roll in.
I Don't disagree
You are proof that LXRP needs a Salesman to get the word out better that they are more than just a MJ company.
I like the technology but as with all companies positioning in the weed sector.. Legalization is the ultimate key
Nice debating on taking a starter position.
I LOVE the new Website!!! Looks like things are gonna start coming together finally. GO $$LXRP$$
Yes....hasn't been much to say
you still in here
Usually a good sign
How many official pat ients have been awarded?
Looks like we have a new website.
The Facebook page is also being refreshed. I got the new web address from there... lexariabioscience.com
The old domain addy seems to still be in use for the time being, but it looks like a new site is up.
LXRP Continues Showcasing Proprietary Research at Cannabis Investment Conferences
- Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods
- Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026
- 19 patent applications filed and pending in more than 40 countries
Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product.
The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers (http://nnw.fm/Uh5R4).
“Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers,” Bunka said in a press release outlining the project.
While Hurricane Irma has postponed Bunka’s next mainstream presentation, slated for the now on-hold Institutional Capital & Cannabis Conference in Miami Beach, Florida, Lexaria continues its drive to showcase the benefits of the company’s unique patented delivery technology (http://nnw.fm/e7OkE).
Lexaria researchers work to solve a critical problem facing the cannabis industry – the fact that most of the CBD and tetrahydrocannabinol (THC) that people consume, through any method, is literally flushed away in the proverbial toilet. To that end, Lexaria has focused on discovering new technologies that can more efficiently deliver cannabinoids to the bloodstream, where they can have their desired effect.
Lexaria’s patented DehydraTECH™ technology solves this problem by delivering cannabinoids in an oral form that masks any undesirable taste but increases bioabsorption, speed of effectiveness and potency. This method of delivery is a more viable and healthier method than smoking or vaping cannabis, a route that non-users and medical providers frown upon due to documented health concerns.
Marijuana is now legal in some form in 29 states and Canada. In fact, the Canadian government is expected to legalize adult use of cannabis in 2018, and there are growing movements in the U.S. to legalize cannabis nationwide, as well. Industry experts predict that U.S. retail sales alone could reach $50 billion by 2026 (http://nnw.fm/0mG2S).
For more information, visit the company’s website at www.LexariaEnergy.com
Nice time to buy in or fill the boat. Warrents expire in 8 days. We should start climbing here soon. Big Pharma talks as well. Finally decent PR. GLA
this company has potential to really explode upwards and real soon this should be a watch alert
61 speakers are listed on the conference website.
using Scat logic... 60 material news releases came out today (other than Lexaria), and 60 mj stocks hit their all-time highs today.
I was at work, so unfortunately I missed that party.
If Chris only networked with the speaker before him (Engel from Organigram), I'm cool with the expense! :)
Considering how much Bunka bought on the open market, investment money is at least partially out of his own pocket money
Not my idea of a holiday.
Another example why Lexaria needs a real salesman:
Lexaria announced it is attending and exhibiting at the Investorshub International Cannabis Conference in Los Angeles on September 1-2, held at the JW Marriott downtown. Chris Bunka, CEO of Lexaria, will be giving a presentation on the latest technology available to benefit the cannabis industry.
No news no hype no nothing except a nice vacation on investors money.
If everyone is a bidwhacker, then no one is a bidwhacker. Let that sink in for a moment.
Hey Pharma, Your move. Ride the wave. Long LXRP
Sure are foreshadowing major deal with pharma company.
So far weak sizzle and still no steak. Still marinating? Hoping so.
SHOW US THE BEEF BUNKA! WE'RE HUNGRY FOR IT.
Landmark M&A Deals Continue to Shape Big Pharma
NetworkNewsWire Editorial Coverage: Merger and acquisition activity has played a massive role in the formation of the pharmaceutical industry as it exists today. Historic deals, like Pfizer’s 2009 purchase of pharmaceutical giant Wyeth for $68 billion and Glaxo Wellcome’s purchase of SmithKline Beecham for $76 billion in 2000, have created a consolidated market that’s often driven forward by the innovations of smaller companies. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) (LXRP Profile), with its promising intellectual property portfolio focused on revolutionizing the delivery of a variety of molecules to the human body, is well-positioned to continue on this history of acquisition in the pharmaceutical space, following in the footsteps of companies like Derma Sciences, Inc., which was acquired by Integra LifeSciences Holdings Corporation (NASDAQ: IART) for approximately $200 million, and CoLucid Pharmaceuticals, Inc., which was acquired by Eli Lilly and Company (NYSE: LLY) in a landmark $960 million deal. With analyst rumblings pointing toward additional high-profile buyouts of industry upstarts like ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Incyte Corp. (NASDAQ: INCY), the time to cash in on the next Big Pharma acquisition could be at hand.
While the acquisition frenzy in pharmaceuticals spans the entirety of the colossal global industry, few subsectors have demonstrated more potential for promising upstarts than the medicinal cannabis market. Projected by Arcview Market Research to eclipse $20.2 billion in North American sales by 2021, the legal marijuana industry, including both medicinal and recreational markets, is expected to create more than a quarter of a million jobs by 2020, outpacing economic mainstays like manufacturing, utilities and government positions. This forecast expansion has already set the stage for a number of industry acquisitions, many of which have taken place in the soon-to-be federally legalized Canadian market. One such is example Canopy Growth Corp.’s April acquisition of rTrees Producers Limited, a late-stage Access to Cannabis for Medical Purposes Regulations (“ACPMR”) applicant. The rTrees acquisition brought a 90,000 square foot indoor growing facility with considerable room for expansion under Canopy Growth’s already sizable umbrella, expanding upon the market presence of the first Canadian cannabis company to achieve a $1 billion market valuation.
Other industry players have followed Canopy Growth’s lead. In late July, Aurora Cannabis announced plans to make a strategic investment in Hempco Food and Fiber, Inc., one of the world’s largest producers of industrial hemp products. Earlier that same month, Canadian cannabis producer Invictus MD Strategies Corp. invested $5.5 million in AB Ventures, Inc. to fund the costs of licensing approval under the ACMPR and construction of related production facilities. Similar M&A deals were recently completed by Aphria, which invested $11.5 million in endocannabinoid-focused pharmaceutical company Scientus Pharma in mid-August, and Maricann Group, Inc., which recently announced its acquisition of biotech company NanoLeaf Technologies for total transaction consideration of C$40.1 million. The NanoLeaf transaction is particularly intriguing for prospective investors of Lexaria Bioscience, as NanoLeaf possesses “the licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug delivery formulations.”
This recent industry activity highlights the rising demand for innovative and marketable offerings targeting the burgeoning cannabis sector, but they fail to capture the scale of a potential Lexaria Bioscience transaction. This is because of the wide-ranging applications of Lexaria’s technology platform. To date, the company has noted potential applications for its lipid-based molecular delivery technology that include NSAIDs, nicotine, vitamins and cannabinoids – applications that are supported by 19 currently-pending patents filed in more than 40 countries. According to biotech analysis firm EvaluatePharma, the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the global market for vitamins in on course to reach $9.3 billion by 2020, the market for alternative nicotine delivery technologies is at an all-time high following recent FDA proposals, and consumer sales of cannabinoids are expected to reach $2.1 billion by 2020. All told, the market potential for Lexaria’s flagship platform could be huge.
It has been precisely this potential, alongside numerous clinical, financial and IP developments, that has driven Lexaria’s growth in recent months. On July 18, the company announced (http://nnw.fm/wI0LB) that the Australian Patent Office granted a patent protecting its method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. This milestone was particularly noteworthy in that it followed Lexaria’s announcement of a $1 million combined R&D program aimed at examining improvement in absorption offered by its technology for several groups of molecules, including NSAIDs, nicotine, vitamins and cannabinoids. Just last week, the company took a major step toward maximizing on the value of its patented technology by announcing the world’s first clinical study of human volunteers of CBD within its high absorption TurboCBD™ product.
“Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexaria’s unique patented delivery technology,” Chris Bunka, CEO of Lexaria, stated in the news release announcing the study. “Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers.”
Strengthening Lexaria’s status as a promising acquisition target is its current cash position. The company has outlined a number of moves to bolster its balance sheet in recent months, most notably its $1 million raise from warrant exercise originally announced on May 19. In total, Lexaria raised over $3 million in the past nine months in a strategic effort to capitalize on the growth of both the pharmaceutical industry as a whole and, perhaps more importantly, the cannabis sector. With funding in place through 2019, according to Bunka, Lexaria has the IP and the capital needed to properly demonstrate the marketability of its lipid-based delivery technology while working with prospective licensees and resellers to maximize returns for early investors.
Recent acquisitions in the pharmaceuticals industry highlight the potential upside Lexaria presents to the investment community. Derma Sciences, Inc., for example, operated as a tissue regeneration company at the forefront of research and innovation for the management of acute and chronic wounds prior to its acquisition by Integra LifeSciences Holdings Corp. (NASDAQ: IART) in January of this year. In a slide deck issued following the acquisition, IART noted Derma’s “line of products with patented technologies,” including multiple offerings targeting the burn and wound management market, as a key driver for the transaction. Insights from medical technology analysis firm MedMarket Diligence, LLC suggest that this market is currently growing at a rate of 3.1 percent annually, providing a fertile runway for future sales growth in the space. For comparison, the cannabinoid market, which is just one of many potential indications for Lexaria’s molecular delivery technology, is expected to climb 700 percent from 2016-2020.
Eli Lilly and Company’s (NYSE: LLY) March acquisition of CoLucid Pharmaceuticals, Inc. serves as another example of the aggressive M&A strategy employed by some of the most recognizable names in Big Pharma. At the time of the deal, David R. Ricks, president and chief executive officer of Eli Lilly, noted that the purchase would “enhance Lilly’s existing pain management portfolio and add a potential near-term launch to [its] late-stage pipeline.” This late-stage addition is lasmiditan, an oral tablet that’s currently being evaluated in phase III clinical trials for the acute treatment of migraine headaches in adults. Lasmiditan was actually originally developed by Eli Lilly, but it was licensed to CoLucid in 2005 as part of Lilly’s strategic move away from the pain management market. On top of highlighting the evolving strategies of Big Pharma players to capitalize on industry trends – including cannabis painkillers and related cannabinoid products – the CoLucid acquisition’s focus within the migraine drug market falls well within earshot of Lexaria’s diverse portfolio of potential applications for its lipid-based delivery technology.
In both of these cases, high-dollar acquisitions were fueled by strong intellectual property positions targeting inviting markets within the pharmaceutical industry. This trend rings true when studying other upstart companies that could be in line for big time buyouts. A buyout of ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) has been rumored for months, with the company having reportedly received an offer from AstraZeneca in February and interest from Pfizer related to its lead product NUPLAZID®, the only significant compound in the company’s development pipeline. Approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease, NUPLAZID® is currently in late stage trials for similar symptoms in Alzheimer’s and schizophrenia, giving it the potential to address a massive and growing global market. The company’s stock closed at $36.16 on September 1, and reports from Seeking Alpha suggest that ACADIA’s management team is pushing for a substantial premium for a potential buyout in the range of “$55 to $60 a share.”
Incyte Corp. (NASDAQ: INCY) is another prime buyout target, as reported in an editorial piece published by MarketWatch. “Incyte is a throwback to what biotech companies were meant to be,” RBC Capital Markets analyst Simos Simeonidis told MarketWatch. “It’s built on ‘great science’ that has helped it develop several drugs, and it continually reinvests in its own research.” Incyte’s main product, Jakafi, is an FDA-approved medication used to treat rare blood cancers. Back in March, analysts speculated that Gilead was close to an agreement to acquire Incyte. Although that deal has not yet come to fruition, the Delaware-based company offers a combination of growing revenues and strong R&D programs that makes it a solid acquisition target, particularly as disappointing clinical data from competing trials strengthen the revenue outlook of Incyte’s leading product.
As demonstrated by recent industry activity, Big Pharma’s biggest names stay active on the M&A front, especially as it relates to first-of-their-kind advancements in promising markets. Continued interest in the pipelines of upstarts like ACADIA Pharmaceuticals and Incyte Corporation paints an intriguing picture as Lexaria Bioscience progresses with the world’s first clinical study of CBD within its high absorption TurboCBD™ product. With a strong balance sheet and an increasingly diverse and wide-reaching IP portfolio targeting some of the industry’s highest growth verticals, Lexaria should be on the radar of any investor hoping to cash in on the M&A deal-making bonanza that could be on the horizon.
For more information on Lexaria Bioscience Corp., please visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.
interesting new trademark app... DehydraTECH.
https://www.trademarks411.com/marks/87581570-dehydratech
Makes sense as it covers the tech process across the board.
Great close for the week, I'm looking forward to some Great news too soon!
Finally a day for the good guys, have a great long weekend Y'ALLS
Little pushback from the good guys late in the day
Lexaria investor deck shows up again in the new CANNAINVESTOR magazine (Canadian edition) ...
https://view.joomag.com/canadian-cannainvestor-magazine-august-september-2017/0420200001502821054?
The LXRP chart gets some tech analysis in the issue as well.
LXRP Begins Laboratory Venture with National Research Council
- Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities
- Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships
- LXRP names Allan Spissinger acting chief financial officer
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council (“NRC”) (http://nnw.fm/ujFU0). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such as beverages, foods, capsules and others means.
LXRP has also named Allan Spissinger (http://nnw.fm/kcVB3) as its acting chief financial officer, secretary and treasurer. He has been with the company since September 2014, when he joined as corporate controller. A CPA, he has more than 10 years’ experience in corporate IT infrastructure and software development before focusing of finance and accounting.
The firm, based in Kelowna, British Columbia, Canada, is a food biosciences company which is a technology disrupter for edible CBDs. It markets a high absorption hemp oil formulation for exotic teas, protein energy bars and high absorption hemp oil capsules that aid in the body’s absorption of CBDs. It is focusing on developing more products for the edible cannabis market.
The joint research venture with the NRC will use advanced analytical techniques. Practical application of the resulting research could broaden or strengthen LXRP’s intellectual property portfolio and even lead to additional commercial arrangements, per a recent statement from the company.
LXRP has a number of international patents, including the recent 20-year effective patent approval issued by Australia (http://nnw.fm/R0nZZ) for the company’s edible cannabis absorption method, time of onset and taste of cannabinoid’s active agents in food.
“We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles using our technology in Australia,” Chris Bunka, chief executive officer of LXRP, stated in a news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.”
A similar patent was granted in the U.S. in 2016, and Bunka added that LXRP anticipates progress on its patent portfolios throughout the remainder of 2017 and into 2018. In the U.S., the company successfully filed a provisional patent application (http://nnw.fm/Gle8p) and stock and option awards in June 2017. It expands the company’s existing patent in the U.S. to microwave processing.
For more information, visit the company’s website at www.LexariaEnergy.com
So long as the results are marketable. Let's keep our fingers crossed. With the known health benefits to CBD, I am hoping that we are able to make substantive waves in the industry with the results of the studies.
Validation of technology is key to LXRP gaining clients/revenue going forward; these clinical studies will be gold down the line.
Buy-Hold-Retire before your old,
Knife
for anyone who thinks this product is a joke or illegitimate why would now two big research departments take on a useless project.
IMO this is huge news with such a reputable school research department on board
Followers
|
219
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
34638
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |